Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Genetics Raises $20M in Series C Financing

NEW YORK (GenomeWeb) – Molecular diagnostics firm Atlas Genetics today announced the completion of a Series C financing round that raised $20 million. 

Atlas will use the proceeds to accelerate the launch of its MDx system called io in Europe for the ultra-rapid diagnosis of infectious diseases, initiate clinical trials in the US, and expand its test menu for sexually transmitted diseases and hospital-acquired infections. 

Participants in the financing included new investor RMI Partners. Existing investors Novartis Venture Funds; Consort Medical; Johnson & Johnson Innovation; Life Science Partners; BB Biotech Ventures; and South West Ventures Fund also participated in the round. 

Based in Bath,UK, Atlas develops infectious disease diagnostics tests and anticipates launching its io platform later this year with a chlamydia test, it said. The system uses electrochemical sensor technology with fully integrated cartridges that contain all reagents on board to receive unprocessed clinical specimens. 

The cartridges are inserted into the reader instrument that then does sample preparation, DNA amplification, and electrochemical detection to analyze the patient sample. Each cartridge can carry as many as 24 different tests from one patient sample, Atlas said, adding that io can conduct sample to answer processing in less than 30 minutes. 

Atlas raised £16.9 million in a Series B financing round in April 2014.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.